Combined disruption of both the MEK/ERK and the IL-6R/STAT3 pathways is required to induce apoptosis of multiple myeloma cells in the presence of bone marrow stromal cells

被引:105
作者
Chatterjee, M
Stühmer, T
Herrmann, P
Bommert, K
Dörken, B
Bargou, RC
机构
[1] Humboldt Univ, Robert Rossle Canc Ctr, Dept Hematol Oncol & Tumorimmunol, D-13122 Berlin, Germany
[2] Humboldt Univ, Charite, Max Delbruck Ctr Mol Med, HELIOS Clin, D-13122 Berlin, Germany
关键词
D O I
10.1182/blood-2004-04-1670
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The interleukin-6 receptor (IL-6R)/signal transducer and activator of transcription 3 (STAT3) pathway contributes to the pathogenesis of multiple myeloma (MM) and protects MM cells from apoptosis. However, MM cells survive the IL-6R blockade If they are cocultured with bone marrow stromal cells (BMSCs), suggesting that the BM microenvironment stimulates IL-6-independent pathways that exert a pro-survival effect. The goal of this study was to investigate the underlying mechanism. Detailed pathway analysis revealed that BMSCs stimulate STAT3 via the IL-6R, and mitogen-activated protein (MAP) kinases via IL-6R-independent mechanisms. Abolition of MEK1,2 activity with PD98059, or ERK1,2 small interfering RNA knockdown, was insufficient to induce apoptosis. However, the combined disruption of the IL-6R/STAT3 and MEK1,2 ERK1,2 pathways led to strong Induction of apoptosis even in the presence of BMSCs. This effect was observed with MM cell lines and with primary MM cells, suggesting that the BMSC-induced activation of MEK1,2/ERK1,2 renders MM cells IL-6R/STAT3 independent. Therefore, in the presence of cells from the BM microenvironment, combined targeting of different (and independently activated) pathways Is required to efficiently induce apoptosis of MM cells. This might have direct implications for the development of future therapeutic strategies for MM. (C) 2004 by The American Society of Hematology.
引用
收藏
页码:3712 / 3721
页数:10
相关论文
共 40 条
  • [1] Barille-Nion Sophie, 2003, Hematology Am Soc Hematol Educ Program, P248
  • [2] Treatment of multiple myeloma
    Barlogie, B
    Shaughnessy, J
    Tricot, G
    Jacobson, J
    Zangari, M
    Anaissie, E
    Walker, R
    Crowley, J
    [J]. BLOOD, 2004, 103 (01) : 20 - 32
  • [3] Billadeau D, 1997, CANCER RES, V57, P2268
  • [4] BILLADEAU D, 1995, CANCER RES, V55, P3640
  • [5] Induction of an interferon response by RNAi vectors in mammalian cells
    Bridge, AJ
    Pebernard, S
    Ducraux, A
    Nicoulaz, AL
    Iggo, R
    [J]. NATURE GENETICS, 2003, 34 (03) : 263 - 264
  • [6] Interleukin-6-dependent gene expression profiles in multiple myeloma INA-6 cells reveal a Bcl-2 family-independent survival pathway closely associated with Stat3 activation
    Brocke-Heidrich, K
    Kretzschmar, AK
    Pfeifer, G
    Henze, C
    Löffler, D
    Koczan, D
    Thiesen, HJ
    Burger, R
    Gramatzki, M
    Horn, F
    [J]. BLOOD, 2004, 103 (01) : 242 - 251
  • [7] A system for stable expression of short interfering RNAs in mammalian cells
    Brummelkamp, TR
    Bernards, R
    Agami, R
    [J]. SCIENCE, 2002, 296 (5567) : 550 - 553
  • [8] Burger R, 2001, Hematol J, V2, P42, DOI 10.1038/sj.thj.6200075
  • [9] BONE-MARROW MICROENVIRONMENT AND THE PROGRESSION OF MULTIPLE-MYELOMA
    CALIGARISCAPPIO, F
    GREGORETTI, MG
    MERICO, F
    GOTTARDI, D
    GHIA, P
    PARVIS, G
    BERGUI, L
    [J]. LEUKEMIA & LYMPHOMA, 1992, 8 (1-2) : 15 - 22
  • [10] Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells
    Catlett-Falcone, R
    Landowski, TH
    Oshiro, MM
    Turkson, J
    Levitzki, A
    Savino, R
    Ciliberto, G
    Moscinski, L
    Fernández-Luna, JL
    Nuñez, G
    Dalton, WS
    Jove, R
    [J]. IMMUNITY, 1999, 10 (01) : 105 - 115